Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Successful treatment with weekly high-dose erlotinib against meningeal metastases from epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma.

Respiratory investigation - 1 Sept 2016

Kanemaru Ryota, Morio Yoshiteru, Takekawa Hidenori, Jo Hitomi, Kasuga Fumiko, Koyama Ryo, Shiota Satomi, Nagaoka Tetsutaro, Takahashi Kazuhisa

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to ErbB Receptors
Share to Erlotinib Hydrochloride

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to EGFR gene

Share to Lung Neoplasms

Share to Meningeal Neoplasms

Share to Mutation

Source

Identifiers

PMID: 27566387
DOI: 10.1016/j.resinv.2016.04.001

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Successful treatment with weekly high-dose erlotinib against meningeal metastases from epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma.PMID 27566387Read ↗

High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs.Semantic proximity Read ↗

Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation.Semantic proximity Read ↗

Erlotinib plus bevacizumab as an effective treatment for leptomeningeal metastases from EGFR mutation-positive non-small cell lung cancer.Semantic proximity Read ↗

Combination treatment with bevacizumab plus erlotinib for meningeal carcinomatosis of afatinib-resistant EGFR mutated lung cancer without T790M mutation: a case report.Semantic proximity Read ↗

High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer.Semantic proximity Read ↗

Erlotinib for Progressive Brain and Leptomeningeal Metastases From HER2-positive Breast Cancer After Treatment Failure With Trastuzumab and Lapatinib: Experience and Review of Literature.Semantic proximity Read ↗

Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report.Semantic proximity Read ↗

Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib.Semantic proximity Read ↗

Intrathecal pemetrexed in patients with EGFR-TKI resistant refractory leptomeningeal metastasis lung adenocarcinoma : a retrospective studySemantic proximity Read ↗

Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib.Semantic proximity Read ↗

Primary CNS Metastatic BRAF-mutated Lung Adenocarcinoma With Complete Intracranial Response to BRAF/MEK Inhibition.Semantic proximity Read ↗

Erlotinib in symptomatic brain metastases from a lung adenocarcinoma with a sensitizing EGFR mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.